EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics

Iryna Halabitska, Pavlo Petakh, Iryna Kamyshna, Oleh Lushchak, Oleksandr Kamyshnyi

Frontiers in Behavioral Neuroscience · 02.11.2026 · 20

DOI: 10.3389/fnbeh.2026.1957516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Behavioral Neuroscience, online erschienen am 02.11.2026. Verfasst von Iryna Halabitska und 4 weiteren Autor:innen. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-traumatic stress disorder (PTSD) is increasingly recognized as a systemic disorder closely linked to metabolic dysfunction, including obesity, insulin resistance, type 2 diabetes and cardiovascular disease. These comorbidities are associated with poorer treatment response, yet pharmacological options for PTSD remain limited. Here, we review evidence that PTSD and metabolic disease share convergent mechanisms, including dysregulation of the hypothalamic–pituitary–adrenal axis, glucocorticoid receptor signaling, neuroinflammation, insulin resistance and mitochondrial dysfunction. We evaluate the rationale for repurposing approved cardiometabolic drugs, including glucagon-like peptide-1 receptor agonists, insulin sensitizers, statins, renin–angiotensin system modulators and glial-targeting agents. We critically assess preclinical and clinical evidence, highlight current limitations and propose a biomarker-guided framework to match therapies to dominant biological mechanisms. Finally, we discuss the exceptional burden of PTSD with cardiometabolic disease in war-affected Ukraine as a priority setting for future mechanism-based clinical trials. Drug repurposing represents a promising, but unproven, precision-psychiatry strategy.

Zitieren

APA

Halabitska, I., Petakh, P., Kamyshna, I., Lushchak, O., & Kamyshnyi, O. (2026). Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics. Frontiers in Behavioral Neuroscience, 20. https://doi.org/10.3389/fnbeh.2026.1957516

Vancouver

Halabitska I, Petakh P, Kamyshna I, Lushchak O, Kamyshnyi O. Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics. Frontiers in Behavioral Neuroscience. 2026;20. doi:10.3389/fnbeh.2026.1957516

BibTeX
@article{Halabitska2026,
  author = {Halabitska, Iryna and Petakh, Pavlo and Kamyshna, Iryna and Lushchak, Oleh and Kamyshnyi, Oleksandr},
  title = {Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics},
  journal = {Frontiers in Behavioral Neuroscience},
  year = {2026},
  volume = {20},
  doi = {10.3389/fnbeh.2026.1957516}
}
Kostenlos starten →